GUS, a fully human IgG1λ monoclonal against the p19 subunit of IL‐23 (IL‐23p19), has been shown to be effective and have a favorable safety profile in the treatment of psoriasis in previous clinical trials.9, 10, 11, 12, 13. Here, IL23A is linked to psoriasis.